![For the Majority of Advanced Malignancies, Combination Immunotherapy Offers No Additional Benefits, According to a Meta-Analysis](https://assignmentpoint.com/wp-content/uploads/2023/10/For-the-Majority-of-Advanced-Malignancies-Combination-Immunotherapy-Offers-No-Additional-Benefits-According-to-a-Meta-Analysis.webp)
Medical
For the Majority of Advanced Malignancies, Combination Immunotherapy Offers No Additional Benefits, According to a Meta-Analysis
According to a recent Northwestern Medicine meta-analysis published in JAMA Oncology, nivolumab plus ipilimumab immunotherapy treatment was not associated with an improvement in survival for…